IRADIMED CORPORATION — Q1 2024 Form 10-Q
Business and period: Unaudited results for the three months ended March 31, 2024, compared with Q1 2023. IRADIMED develops, manufactures and sells MRI-compatible medical devices, accessories, disposables and services, primarily to hospitals and acute-care facilities.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $17.60 million | $15.48 million | +13.7% |
| Gross profit / margin | $13.39 million / 76.1% | $11.72 million / 75.7% | Margin +0.4 percentage points |
| Operating income / margin | $4.75 million / 27.0% | $4.01 million / 25.9% | Higher |
| Net income / diluted EPS | $4.14 million / $0.32 | $3.41 million / $0.27 | Higher |
| Operating cash flow | $3.88 million | $4.65 million | Lower |
Revenue growth reflected stronger patient vital signs monitor, disposable and service sales. Patient vital signs monitoring systems revenue rose to $6.46 million from $4.70 million; IV infusion pump systems revenue declined to $5.19 million from $5.54 million. U.S. revenue increased 11.9% to $13.41 million, while international revenue increased 19.8% to $4.19 million.
Sales and marketing expense increased 27.6% to $3.83 million, primarily from commissions, sales activity, payroll and benefits. General and administrative expense rose 1.8% to $3.99 million; research and development was approximately $0.82 million, broadly flat. Other income increased to $0.50 million, primarily from higher interest earned on cash investments. Effective tax rate was 21.1%, versus 21.7%.
Liquidity, cash flow and balance sheet
- Cash and cash equivalents were $45.1 million at March 31, down from $49.8 million at year-end. Working capital was $64.3 million, versus $59.7 million; stockholders’ equity was $76.1 million.
- Cash from operations was $3.9 million. Investing activities used $0.48 million, mainly property and equipment and capitalized intangible assets; Q1 2023 investing outflow was $6.56 million, including the $6.2 million land purchase in 2023.
- Financing activities used $8.04 million, primarily for dividends. No borrowings are presented on the balance sheet; operating lease liabilities totaled approximately $1.94 million.
- Management says existing cash and anticipated operating cash flow should fund operations for at least 12 months and into the foreseeable future. The company plans improvements to land acquired for future office, assembly, warehouse and shipping capacity, potentially over the next two or so years.
Outlook, risks and other notable matters
- Management expects higher revenue for the remainder of 2024 than the comparable 2023 period, driven by medical devices, accessories, disposables and services. It also expects higher operating expenses, particularly sales and marketing, regulatory, and general and administrative costs. No numerical guidance was provided.
- Key disclosed risks include reliance on a limited product range, FDA and other regulatory clearances and inspections, sole-sourced critical components, supply interruption, product liability or recalls, competition, and lengthening sales cycles.
- Purchase commitments totaled $6.51 million at March 31. The company reported approximately $250,000 accrued for legal matters and does not expect pending matters to have a material adverse effect.
- The Winter Springs manufacturing and headquarters facility is leased from an entity controlled by CEO and Chairman Roger Susi. The company paid that entity $129,482 in Q1 2024. The lease is scheduled to expire in May 2024 but is expected to renew under its terms; management says it will reassess lease assumptions as plans for a new facility are finalized.
- On May 2, 2024, the board declared a regular quarterly dividend of $0.15 per share, payable May 30 to holders of record May 20. Management states the policy is subject to board discretion and applicable law.
- Management reported effective disclosure controls and no material change in risk factors from the 2023 Annual Report.
Important facts for investors to verify
- Whether growth in monitoring systems, disposables and services can continue, and whether the decline in infusion pump sales persists.
- Execution, cost and timing of the planned facility expansion, and the related use of cash alongside dividend payments.
- Regulatory status and supply continuity for products dependent on FDA clearances and sole-sourced components.
- The filing’s cash-flow statement reports ending cash of $45,126,674, while the balance sheet reports $45,126,676; the MD&A operating cash-flow figure also differs by $2 from the cash-flow statement. The filing text does not explain these small discrepancies.